Search

Your search keyword '"Mook, S."' showing total 303 results
Start Over Author "Mook, S."
303 results on '"Mook, S."'

4. Technical feasibility of Magnetic Resonance Fingerprinting on a 1.5T MRI-Linac

Author

Bruijnen, T., van der Heide, O., Intven, M. P. W., Mook, S., Lagendijk, J. J. W., Berg, C. A. T. van den, and Tijssen, R. H. N.

Subjects
Physics - Medical Physics
Abstract

Hybrid MRI-linac (MRL) systems enable daily multiparametric quantitative MRI to assess tumor response to radiotherapy. Magnetic Resonance Fingerprinting (MRF) may provide time efficient means of rapid multiparametric quantitative MRI. The accuracy of MRF, however, relies on adequate control over system imperfections, such as eddy currents and B1+, which are different and not as well established on MRL systems compared to diagnostic systems. In this study we investigate the technical feasibility of gradient spoiled 2D MRF on a 1.5T MRL. We show with phantom experiments that the MRL generates reliable MRF signals that are temporally stable during the day and have good agreement with spin-echo reference measurements. Subsequent in-vivo MRF scans in healthy volunteers and a patient with a colorectal liver metastasis showed good image quality, where the quantitative values of selected organs corresponded with the values reported in literature. Therefore we conclude that gradient spoiled 2D MRF is feasible on a 1.5T MRL with similar performance as on a diagnostic system. The precision and accuracy of the parametric maps are sufficient for further investigation of the clinical utility of MRF for online quantitatively MRI-guided radiotherapy., Comment: 17 pages, 9 figures, Submitted to Physics in Medicine & Biology as a technical note

Published
2020
Full Text
View/download PDF

5. Effect of a prediction tool and communication skills training on communication of treatment outcomes: a multicenter stepped wedge clinical trial (the SOURCE trial)

Author

van de Water, L.F., Kuijper, S.C., Henselmans, I., van Alphen, E.N., Kooij, E.S., Calff, M.M., Beerepoot, L.V., Buijsen, J., Eshuis, W.J., Geijsen, E.D., Havenith, S.H.C., Heesakkers, F.F.B.M., Mook, S., Muller, K., Post, H.C., Rütten, H., Slingerland, M., van Voorthuizen, T., van Laarhoven, H.W.M., and Smets, E.M.A.

Published
2023
Full Text
View/download PDF

15. PO-1385 Clinical outcomes after MR-guided radiotherapy for pancreatic tumors on a 1.5 T MR-linac

Author

Eijkelenkamp, H., primary, Grimbergen, G., additional, Daamen, L., additional, Heerkens, H., additional, van de Ven, S., additional, Mook, S., additional, Meijer, G., additional, Molenaar, I.Q., additional, van Santvoort, H., additional, Paulson, E., additional, Erickson, B., additional, Verkooijen, H., additional, Hall, W.A., additional, and Intven, M., additional

Published
2023
Full Text
View/download PDF

16. Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: A Delphi consensus study in Europe

Author

Kroese, T.E., Laarhoven, H.W.M. van, Schoppman, S.F., Deseyne, P., Cutsem, E. Van, Haustermans, K., Nafteux, P., Thomas, M., Obermannova, R., Mortensen, H.R., Nordsmark, M., Pfeiffer, P., Elme, A., Adenis, A., Piessen, G., Bruns, C.J., Lordick, F., Gockel, I., Moehler, M., Gani, C., Liakakos, T., Reynolds, J., Morganti, A.G., Rosati, R., Castoro, C., Cellini, F., D'Ugo, D., Roviello, F., Bencivenga, M., Manzoni, G. de, Henegouwen, M.I. van Berge, Hulshof, M., Dieren, J. van, Vollebergh, M., Sandick, J.W. van, Jeene, P., Muijs, C.T., Slingerland, M., Voncken, F.E.M., Hartgrink, H., Creemers, G.J., Sangen, M.J. van der, Nieuwenhuijzen, G., Berbee, M., Verheij, M., Wijnhoven, B., Beerepoot, L.V., Mohammad, N.H., Mook, S., Ruurda, J.P., Kolodziejczyk, P., Polkowski, W.P., Wyrwicz, L., Alsina, M., Pera, M., Kanonnikoff, T.F., Cervantes, A., Nilsson, M., Monig, S., Wagner, A.D., Guckenberger, M., Griffiths, E.A., Smyth, E., Hanna, G.B., Markar, S., Chaudry, M.A., Hawkins, M.A., Cheong, E., Rütten, H., Gootjes, E.C., Hillegersberg, R. van, Rossum, P.S.N. van, Kroese, T.E., Laarhoven, H.W.M. van, Schoppman, S.F., Deseyne, P., Cutsem, E. Van, Haustermans, K., Nafteux, P., Thomas, M., Obermannova, R., Mortensen, H.R., Nordsmark, M., Pfeiffer, P., Elme, A., Adenis, A., Piessen, G., Bruns, C.J., Lordick, F., Gockel, I., Moehler, M., Gani, C., Liakakos, T., Reynolds, J., Morganti, A.G., Rosati, R., Castoro, C., Cellini, F., D'Ugo, D., Roviello, F., Bencivenga, M., Manzoni, G. de, Henegouwen, M.I. van Berge, Hulshof, M., Dieren, J. van, Vollebergh, M., Sandick, J.W. van, Jeene, P., Muijs, C.T., Slingerland, M., Voncken, F.E.M., Hartgrink, H., Creemers, G.J., Sangen, M.J. van der, Nieuwenhuijzen, G., Berbee, M., Verheij, M., Wijnhoven, B., Beerepoot, L.V., Mohammad, N.H., Mook, S., Ruurda, J.P., Kolodziejczyk, P., Polkowski, W.P., Wyrwicz, L., Alsina, M., Pera, M., Kanonnikoff, T.F., Cervantes, A., Nilsson, M., Monig, S., Wagner, A.D., Guckenberger, M., Griffiths, E.A., Smyth, E., Hanna, G.B., Markar, S., Chaudry, M.A., Hawkins, M.A., Cheong, E., Rütten, H., Gootjes, E.C., Hillegersberg, R. van, and Rossum, P.S.N. van

Abstract

Item does not contain fulltext, BACKGROUND: Local treatment improves the outcomes for oligometastatic disease (OMD, i.e. an intermediate state between locoregional and widespread disseminated disease). However, consensus about the definition, diagnosis and treatment of oligometastatic oesophagogastric cancer is lacking. The aim of this study was to develop a multidisciplinary European consensus statement on the definition, diagnosis and treatment of oligometastatic oesophagogastric cancer. METHODS: In total, 65 specialists in the multidisciplinary treatment for oesophagogastric cancer from 49 expert centres across 16 European countries were requested to participate in this Delphi study. The consensus finding process consisted of a starting meeting, 2 online Delphi questionnaire rounds and an online consensus meeting. Input for Delphi questionnaires consisted of (1) a systematic review on definitions of oligometastatic oesophagogastric cancer and (2) a discussion of real-life clinical cases by multidisciplinary teams. Experts were asked to score each statement on a 5-point Likert scale. The agreement was scored to be either absent/poor (<50%), fair (50%-75%) or consensus (≥75%). RESULTS: A total of 48 experts participated in the starting meeting, both Delphi rounds, and the consensus meeting (overall response rate: 71%). OMD was considered in patients with metastatic oesophagogastric cancer limited to 1 organ with ≤3 metastases or 1 extra-regional lymph node station (consensus). In addition, OMD was considered in patients without progression at restaging after systemic therapy (consensus). For patients with synchronous or metachronous OMD with a disease-free interval ≤2 years, systemic therapy followed by restaging to consider local treatment was considered as treatment (consensus). For metachronous OMD with a disease-free interval >2 years, either upfront local treatment or systemic treatment followed by restaging was considered as treatment (fair agreement). CONCLUSION: The OMEC project has resul

Published
2023

17. Recommendations for improved reproducibility of ADC derivation on behalf of the Elekta MRI-linac consortium image analysis working group.

Author

Bisgaard, A.L.H., Keesman, R., Lier, A.L.H.M.W. van, Coolens, C., Houdt, P.J. van, Tree, A., Wetscherek, A., Romesser, P.B., Tyagi, N., Russo, M. Lo, Habrich, J., Vesprini, D., Lau, A.Z., Mook, S., Chung, P., Kerkmeijer, L.G.W., Gouw, Z.A.R., Lorenzen, E.L., Heide, U.A. van der, Schytte, T., Brink, C., Mahmood, F., Bisgaard, A.L.H., Keesman, R., Lier, A.L.H.M.W. van, Coolens, C., Houdt, P.J. van, Tree, A., Wetscherek, A., Romesser, P.B., Tyagi, N., Russo, M. Lo, Habrich, J., Vesprini, D., Lau, A.Z., Mook, S., Chung, P., Kerkmeijer, L.G.W., Gouw, Z.A.R., Lorenzen, E.L., Heide, U.A. van der, Schytte, T., Brink, C., and Mahmood, F.

Abstract

01 september 2023, Contains fulltext : 295938.pdf (Publisher’s version ) (Open Access), BACKGROUND AND PURPOSE: The apparent diffusion coefficient (ADC), a potential imaging biomarker for radiotherapy response, needs to be reproducible before translation into clinical use. The aim of this study was to evaluate the multi-centre delineation- and calculation-related ADC variation and give recommendations to minimize it. MATERIALS AND METHODS: Nine centres received identical diffusion-weighted and anatomical magnetic resonance images of different cancerous tumours (adrenal gland, pelvic oligo metastasis, pancreas, and prostate). All centres delineated the gross tumour volume (GTV), clinical target volume (CTV), and viable tumour volume (VTV), and calculated ADCs using both their local calculation methods and each of the following calculation conditions: b-values 0-500 vs. 150-500 s/mm(2), region-of-interest (ROI)-based vs. voxel-based calculation, and mean vs. median. ADC variation was assessed using the mean coefficient of variation across delineations (CV(D)) and calculation methods (CV(C)). Absolute ADC differences between calculation conditions were evaluated using Friedman's test. Recommendations for ADC calculation were formulated based on observations and discussions within the Elekta MRI-linac consortium image analysis working group. RESULTS: The median (range) CV(D) and CV(C) were 0.06 (0.02-0.32) and 0.17 (0.08-0.26), respectively. The ADC estimates differed 18% between b-value sets and 4% between ROI/voxel-based calculation (p-values < 0.01). No significant difference was observed between mean and median (p = 0.64). Aligning calculation conditions between centres reduced CV(C) to 0.04 (0.01-0.16). CV(D) was comparable between ROI types. CONCLUSION: Overall, calculation methods had a larger impact on ADC reproducibility compared to delineation. Based on the results, significant sources of variation were identified, which should be considered when initiating new studies, in particular multi-centre investigations.

Published
2023

18. Effect of a prediction tool and communication skills training on communication of treatment outcomes: a multicenter stepped wedge clinical trial (the SOURCE trial).

Author

Water, L.F. van de, Kuijper, S.C., Henselmans, I., Alphen, E.N. van, Kooij, E.S., Calff, M.M., Beerepoot, L.V., Buijsen, J., Eshuis, W.J., Geijsen, E.D., Havenith, S.H.C., Heesakkers, F.F.B.M., Mook, S., Muller, K., Post, H.C., Rütten, H., Slingerland, M., Voorthuizen, T. van, Laarhoven, H.W. van, Smets, E.M.A., Water, L.F. van de, Kuijper, S.C., Henselmans, I., Alphen, E.N. van, Kooij, E.S., Calff, M.M., Beerepoot, L.V., Buijsen, J., Eshuis, W.J., Geijsen, E.D., Havenith, S.H.C., Heesakkers, F.F.B.M., Mook, S., Muller, K., Post, H.C., Rütten, H., Slingerland, M., Voorthuizen, T. van, Laarhoven, H.W. van, and Smets, E.M.A.

Abstract

Item does not contain fulltext, BACKGROUND: For cancer patients to effectively engage in decision making, they require comprehensive and understandable information regarding treatment options and their associated outcomes. We developed an online prediction tool and supporting communication skills training to assist healthcare providers (HCPs) in this complex task. This study aims to assess the impact of this combined intervention (prediction tool and training) on the communication practices of HCPs when discussing treatment options. METHODS: We conducted a multicenter intervention trial using a pragmatic stepped wedge design (NCT04232735). Standardized Patient Assessments (simulated consultations) using cases of esophageal and gastric cancer patients, were performed before and after the combined intervention (March 2020 to July 2022). Audio recordings were analyzed using an observational coding scale, rating all utterances of treatment outcome information on the primary outcome-precision of provided outcome information-and on secondary outcomes-such as: personalization, tailoring and use of visualizations. Pre vs. post measurements were compared in order to assess the effect of the intervention. FINDINGS: 31 HCPs of 11 different centers in the Netherlands participated. The tool and training significantly affected the precision of the overall communicated treatment outcome information (p = 0.001, median difference 6.93, IQR (-0.32 to 12.44)). In the curative setting, survival information was significantly more precise after the intervention (p = 0.029). In the palliative setting, information about side effects was more precise (p < 0.001). INTERPRETATION: A prediction tool and communication skills training for HCPs improves the precision of treatment information on outcomes in simulated consultations. The next step is to examine the effect of such interventions on communication in clinical practice and on patient-reported outcomes. FUNDING: Financial support for this study was provided entirely by

Published
2023

19. Effect of a prediction tool and communication skills training on communication of treatment outcomes: a multicenter stepped wedge clinical trial (the SOURCE trial)

Author

MS MOD, MS KNO, MS Radiotherapie, Cancer, van de Water, L. F., Kuijper, S. C., Henselmans, I., van Alphen, E. N., Kooij, E. S., Calff, M. M., Beerepoot, L. V., Buijsen, J., Eshuis, W. J., Geijsen, E. D., Havenith, S. H.C., Heesakkers, F. F.B.M., Mook, S., Muller, K., Post, H. C., Rütten, H., Slingerland, M., van Voorthuizen, T., van Laarhoven, H. W.M., Smets, E. M.A., MS MOD, MS KNO, MS Radiotherapie, Cancer, van de Water, L. F., Kuijper, S. C., Henselmans, I., van Alphen, E. N., Kooij, E. S., Calff, M. M., Beerepoot, L. V., Buijsen, J., Eshuis, W. J., Geijsen, E. D., Havenith, S. H.C., Heesakkers, F. F.B.M., Mook, S., Muller, K., Post, H. C., Rütten, H., Slingerland, M., van Voorthuizen, T., van Laarhoven, H. W.M., and Smets, E. M.A.

Published
2023

20. Safety and Feasibility of Robot-Assisted Minimally Invasive Esophagectomy (RAMIE) with Three-Field Lymphadenectomy and Neoadjuvant Chemoradiotherapy in Patients with Resectable Esophageal Cancer and Cervical Lymph Node Metastasis

Author

MCS-team, MS CGO, Cancer, MS Hoofd-Hals Chirurgische Oncologie, Other research (not in main researchprogram), MS Radiotherapie, Pathologie Pathologen staf, MS MDL 1, van der Horst, S., Weijs, T. J., Braunius, W. W., Mook, S., Mohammed, N. Haj, Brosens, L., van Rossum, P. S.N., Weusten, B. L.A.M., Ruurda, J. P., van Hillegersberg, R., MCS-team, MS CGO, Cancer, MS Hoofd-Hals Chirurgische Oncologie, Other research (not in main researchprogram), MS Radiotherapie, Pathologie Pathologen staf, MS MDL 1, van der Horst, S., Weijs, T. J., Braunius, W. W., Mook, S., Mohammed, N. Haj, Brosens, L., van Rossum, P. S.N., Weusten, B. L.A.M., Ruurda, J. P., and van Hillegersberg, R.

Published
2023

21. ASO Visual Abstract: Safety and Feasibility of Robot-Assisted Minimally Invasive Esophagectomy (RAMIE) with Three-Field Lymphadenectomy and Neoadjuvant Chemoradiotherapy in Patients with Resectable Esophageal Cancer and Cervical Lymph Node Metastasis

Author

CTC, MS CGO, Cancer, MS Hoofd-Hals Chirurgische Oncologie, Other research (not in main researchprogram), MS Radiotherapie, MS Medische Oncologie, Pathologie Pathologen staf, MS MDL 1, van der Horst, S., Weijs, T. J., Braunius, W. W., Mook, S., Mohammed, N. Haj, Brosens, L., van Rossum, P. S.N., Weusten, B. L.A.M., Ruurda, J. P., van Hillegersberg, R., CTC, MS CGO, Cancer, MS Hoofd-Hals Chirurgische Oncologie, Other research (not in main researchprogram), MS Radiotherapie, MS Medische Oncologie, Pathologie Pathologen staf, MS MDL 1, van der Horst, S., Weijs, T. J., Braunius, W. W., Mook, S., Mohammed, N. Haj, Brosens, L., van Rossum, P. S.N., Weusten, B. L.A.M., Ruurda, J. P., and van Hillegersberg, R.

Published
2023

24. PO-1754 Delineation-related ADC variation between centres in the Elekta Unity MR linac Consortium

Author

Bisgaard, A., primary, van Lier, A., additional, Coolens, C., additional, Keesman, R., additional, Tree, A., additional, Wetscherek, A., additional, Romesser, P., additional, Tyagi, N., additional, Lo Russo, M., additional, Habrich, J., additional, Vespirini, D., additional, Lau, A., additional, Mook, S., additional, Chung, P., additional, Kerkmeijer, L., additional, Nowee, M., additional, Schytte, T., additional, Lorenzen, E., additional, Brink, C., additional, Van der Heide, U., additional, and Mahmood, F., additional

Published
2022
Full Text
View/download PDF

25. OC-0419 Patterns of Care and Safety in 1800 patients treated on a high-field MR-Linac platform registry

Author

Westerhoff, J., primary, Daamen, L., additional, Christodouleas, J., additional, Blezer, E., additional, Choudhury, A., additional, Westley, R., additional, Erickson, B., additional, Fuller, C., additional, Hafeez, S., additional, van der Heide, U., additional, Intven, M., additional, Kirby, A., additional, Lalondrelle, S., additional, Minsky, B., additional, Mook, S., additional, Nowee, M., additional, Marijnen, C., additional, Orrling, K., additional, Sahgal, A., additional, Schultz, C., additional, Tersteeg, R., additional, Tree, A., additional, Tseng, C., additional, van der Voort van Zyp, J., additional, Verkooijen, H., additional, and Hall, W., additional

Published
2022
Full Text
View/download PDF

27. Treatment decision-making during outpatient clinic visit of patients with esophagogastric cancer. The perspectives of clinicians and patients, a mixed method, multiple case study

Author

Luijten, J., Brom, L., Vissers, Pauline A.J., Wouw, Y.A.J. van de, Warmerdam, F., Heisterkamp, J., Mook, S., Hadj, J. Oulad, Det, M.J. van, Timmermans, L., Hulshof, M., Laarhoven, H.W.M. van, Rosman, C., Siersema, P.D., Westerman, M.J., Verhoeven, R.H.A., Nieuwenhuijzen, G.A., Luijten, J., Brom, L., Vissers, Pauline A.J., Wouw, Y.A.J. van de, Warmerdam, F., Heisterkamp, J., Mook, S., Hadj, J. Oulad, Det, M.J. van, Timmermans, L., Hulshof, M., Laarhoven, H.W.M. van, Rosman, C., Siersema, P.D., Westerman, M.J., Verhoeven, R.H.A., and Nieuwenhuijzen, G.A.

Abstract

Contains fulltext : 251574.pdf (Publisher’s version ) (Open Access), BACKGROUND: The probability of undergoing treatment with curative intent according to the hospital of diagnosis varies for esophagogastric cancer in the Netherlands. Little is known about the factors contributing to this variation. This study aimed to improve the understanding of the differences between the multidisciplinary team meeting treatment proposal and the treatment that was actually carried out and to qualitatively investigate the differences in treatment decision-making after the multidisciplinary team meeting treatment proposal between hospitals. METHODS: To gain an in-depth understanding of treatment decision-making, quantitative data (i.e., multidisciplinary team meeting proposal and treatment that was carried out) were collected from the Netherlands Cancer Registry. Changes in the multidisciplinary team meeting proposal and applied treatment comprised changes in the type of treatment option (i.e., curative or palliative, or no change) and were calculated according to the multivariable multilevel probability of undergoing treatment with curative intent (low, middle, and high). Qualitative data were collected from eight hospitals, including observations of 26 outpatient clinic consultations, 30 in-depth interviews with clinicians, seven focus groups with clinicians, and three focus groups with patients. Clinicians and patients' perspectives were assessed using thematic content analysis. RESULTS: The multidisciplinary team meeting proposal and applied treatment were concordant in 97% of the cases. Clinicians' implementation of treatment decision-making in clinical practice varied, which was mentioned by the clinicians to be due to the clinician's personality and values. Differences between clinicians consisted of discussing all treatment options versus only the best fitting treatment option and the extent of discussing the benefits and harms. Most patients aimed to undergo curative treatment regardless of the consequences, since they believed this could p

Published
2022

28. Patterns of Care and Safety in 1800 patients treated on a high-field MR-Linac platform registry

Author

Trialbureau Beeld, MS CGO, Cancer, Brain, MS Radiotherapie, Arts-assistenten Radiotherapie, Arts Assistenten Cardiologie, Hersenen-Medisch 1, Westerhoff, J., Daamen, L., Christodouleas, J., Blezer, E., Choudhury, A., Westley, R., Erickson, B., Fuller, C., Hafeez, S., van der Heide, U., Intven, M., Kirby, A., Lalondrelle, S., Minsky, B., Mook, S., Nowee, M., Marijnen, C., Orrling, K., Sahgal, A., Schultz, C., Tersteeg, R., Tree, A., Tseng, C., van Zyp, J. van der Voort, Verkooijen, H., Hall, W., Trialbureau Beeld, MS CGO, Cancer, Brain, MS Radiotherapie, Arts-assistenten Radiotherapie, Arts Assistenten Cardiologie, Hersenen-Medisch 1, Westerhoff, J., Daamen, L., Christodouleas, J., Blezer, E., Choudhury, A., Westley, R., Erickson, B., Fuller, C., Hafeez, S., van der Heide, U., Intven, M., Kirby, A., Lalondrelle, S., Minsky, B., Mook, S., Nowee, M., Marijnen, C., Orrling, K., Sahgal, A., Schultz, C., Tersteeg, R., Tree, A., Tseng, C., van Zyp, J. van der Voort, Verkooijen, H., and Hall, W.

Published
2022

29. Clinical implementation and feasibility of long-course fractionated MR-guided chemoradiotherapy for patients with esophageal cancer: An R-IDEAL stage 1b/2a evaluation of technical innovation

Author

Cancer, MS Radiotherapie, Onderzoek Beeld, Fysica Radiotherapie Research, Klinische Fysica RT, Onderzoek Radiotherapie, Boekhoff, M. R., Bouwmans, R., Doornaert, P. A.H., Intven, M. P.W., Lagendijk, J. J.W., van Lier, A. L.H.M.W., Rasing, M. J.A., van de Ven, S., Meijer, G. J., Mook, S., Cancer, MS Radiotherapie, Onderzoek Beeld, Fysica Radiotherapie Research, Klinische Fysica RT, Onderzoek Radiotherapie, Boekhoff, M. R., Bouwmans, R., Doornaert, P. A.H., Intven, M. P.W., Lagendijk, J. J.W., van Lier, A. L.H.M.W., Rasing, M. J.A., van de Ven, S., Meijer, G. J., and Mook, S.

Published
2022

36. Salvage Robot-Assisted Minimally Invasive Esophagectomy (RAMIE) for T4b Esophageal Cancer After Definitive Chemoradiotherapy

Author

Defize, I.L., Horst, S. van der, Bülbul, M., Mohammad, N. Haj, Mook, S., Meijer, G.J., Brosens, L.A.A., Ruurda, J.P., Hillegersberg, R. van, Defize, I.L., Horst, S. van der, Bülbul, M., Mohammad, N. Haj, Mook, S., Meijer, G.J., Brosens, L.A.A., Ruurda, J.P., and Hillegersberg, R. van

Abstract

Contains fulltext : 245231.pdf (Publisher’s version ) (Open Access), BACKGROUND: Patients with esophageal cancer that invades adjacent structures (cT4b) are precluded from surgery and usually treated with definitive chemoradiotherapy (dCRT). dCRT might result in sufficient downstaging to enable a radical resection, possibly improving survival. This study aimed to assess the perioperative and oncologic outcomes of a salvage robot-assisted minimally invasive esophagectomy (RAMIE) in patients with cT4b esophageal cancer after dCRT. METHODS: Between June 2012 and November 2019, patients who underwent a RAMIE with a gastric conduit reconstruction after completion of dCRT for cT4b esophageal carcinoma were identified from a prospectively maintained surgical database at the University Medical Center Utrecht. RESULTS: In total, 24 patients with a histopathologically confirmed T4b adenocarcinoma or squamous cell carcinoma of the esophagus were included. The adjacent organs involved were the tracheobronchial tree (67%), aorta (21%) or both (13%). No conversions or major intraoperative complications were observed. A radical resection was achieved in 22 patients (92%), and a pathologic complete response was observed in 13 (54%) patients. Postoperative grade 2 or higher complications occurred in 20 patients (83%). The disease-free survival at 24 months was 68% for the patients in whom a radical resection was achieved. CONCLUSION: In patients with cT4b esophageal cancer treated with dCRT followed by a salvage RAMIE, a radical resection rate of 92% was achieved, with acceptable complications and promising survival rates. These results demonstrate the feasibility of a curative surgical treatment for patients with initially irresectable esophageal cancer but underscore the importance of a proper preoperative patient selection.

Published
2021

37. CTV-to-PTV margin assessment for esophageal cancer radiotherapy based on an accumulated dose analysis

Author

Fysica Radiotherapie Research, Cancer, MS CGO, Klinische Fysica RT, Onderzoek Beeld, MS Radiotherapie, Boekhoff, M R, Defize, I L, Borggreve, A S, van Hillegersberg, R, Kotte, A N T J, Lagendijk, J J W, van Lier, A L H M W, Ruurda, J P, Takahashi, N, Mook, S, Meijer, G J, Fysica Radiotherapie Research, Cancer, MS CGO, Klinische Fysica RT, Onderzoek Beeld, MS Radiotherapie, Boekhoff, M R, Defize, I L, Borggreve, A S, van Hillegersberg, R, Kotte, A N T J, Lagendijk, J J W, van Lier, A L H M W, Ruurda, J P, Takahashi, N, Mook, S, and Meijer, G J

Published
2021

38. Salvage Robot-Assisted Minimally Invasive Esophagectomy (RAMIE) for T4b Esophageal Cancer After Definitive Chemoradiotherapy

Author

Fysica Radiotherapie Research, Cancer, MS CGO, Longziekten, MS Medische Oncologie, MS Radiotherapie, MS Mondziekten/Kaakchirurgie, Pathologie Pathologen staf, Defize, I L, van der Horst, S, Bülbul, M, Haj Mohammad, N, Mook, S, Meijer, G J, Brosens, L A A, Ruurda, J P, van Hillegersberg, R, Fysica Radiotherapie Research, Cancer, MS CGO, Longziekten, MS Medische Oncologie, MS Radiotherapie, MS Mondziekten/Kaakchirurgie, Pathologie Pathologen staf, Defize, I L, van der Horst, S, Bülbul, M, Haj Mohammad, N, Mook, S, Meijer, G J, Brosens, L A A, Ruurda, J P, and van Hillegersberg, R

Published
2021

39. Online adaptive MR-guided radiotherapy for rectal cancer; feasibility of the workflow on a 1.5T MR-linac; clinical implementation and initial experience

Author

MS Radiotherapie, Cancer, Trialbureau Beeld, Fysica Radiotherapie Research, Klinische Fysica RT, Intven, M P W, de Mol van Otterloo, S R, Mook, S, Doornaert, P A H, de Groot-van Breugel, E N, Sikkes, G G, Willemsen-Bosman, M E, van Zijp, H M, Tijssen, R H N, MS Radiotherapie, Cancer, Trialbureau Beeld, Fysica Radiotherapie Research, Klinische Fysica RT, Intven, M P W, de Mol van Otterloo, S R, Mook, S, Doornaert, P A H, de Groot-van Breugel, E N, Sikkes, G G, Willemsen-Bosman, M E, van Zijp, H M, and Tijssen, R H N

Published
2021

42. PD-0071: The MOMENTUM study, an international registry of patients treated on an MR-linac: 9-month experience

Author

Van Otterloo, S. De Mol, primary, Blezer, E.L.A., additional, Fuller, C.D., additional, Faivre-Finn, C., additional, Sahgal, A., additional, Van der Heide, U.A., additional, Christodouleas, J.P., additional, Akhiat, H., additional, Mook, S., additional, Intven, M.P.W., additional, Van Triest, B., additional, Tree, A.C., additional, Kirby, A.M., additional, Lalondrelle, S., additional, Schultz, C., additional, Erickson, B., additional, Emma, H., additional, Nowee, M.E., additional, Hafeez, S., additional, Oelfke, U., additional, Tersteeg, R.H.A., additional, Eggert, D., additional, Hall, W.A., additional, and Verkooijen, H.M., additional

Published
2020
Full Text
View/download PDF

44. The Patterns of Care, Tolerability and Safety in the First Year of a Novel High Field MR-Linac

Author

de Mol van Otterloo, S.R., primary, Christodouleas, J.P., additional, Blezer, E.L.A., additional, Cobben, D., additional, Erickson, B.A., additional, Fuller, C.D., additional, Hafeez, S., additional, Kirby, A., additional, Lalondrelle, S., additional, Mook, S., additional, Nowee, M.E., additional, Orrling, K., additional, Philippens, M., additional, Sahgal, A., additional, Schultz, C.J., additional, Tree, A., additional, van Triest, B., additional, Tseng, C.L., additional, Hall, W.A., additional, and Verkooijen, H., additional

Published
2020
Full Text
View/download PDF

48. 3-Dimensional target coverage assessment for MRI guided esophageal cancer radiotherapy

Author

Boekhoff, M. R., Defize, I. L., Borggreve, A. S., Takahashi, N., van Lier, A. L.H.M.W., Ruurda, J. P., van Hillegersberg, R., Lagendijk, J. J.W., Mook, S., Meijer, G. J., Boekhoff, M. R., Defize, I. L., Borggreve, A. S., Takahashi, N., van Lier, A. L.H.M.W., Ruurda, J. P., van Hillegersberg, R., Lagendijk, J. J.W., Mook, S., and Meijer, G. J.

Published
2020

49. 3-Dimensional target coverage assessment for MRI guided esophageal cancer radiotherapy

Author

Fysica Radiotherapie Research, Cancer, Perfusie, Onderzoek Radiotherapie, MS Radiotherapie, Klinische Fysica RT, MS CGO, Boekhoff, M. R., Defize, I. L., Borggreve, A. S., Takahashi, N., van Lier, A. L.H.M.W., Ruurda, J. P., van Hillegersberg, R., Lagendijk, J. J.W., Mook, S., Meijer, G. J., Fysica Radiotherapie Research, Cancer, Perfusie, Onderzoek Radiotherapie, MS Radiotherapie, Klinische Fysica RT, MS CGO, Boekhoff, M. R., Defize, I. L., Borggreve, A. S., Takahashi, N., van Lier, A. L.H.M.W., Ruurda, J. P., van Hillegersberg, R., Lagendijk, J. J.W., Mook, S., and Meijer, G. J.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results